Cure8 research brief
This study reports real-world outcomes with granulocyte and monocyte adsorptive apheresis (GMA) in patients with refractory IBD, showing steroid-free remission by week 14 in about one-third of patients and continued benefit for some on longer maintenance — information that may matter to patients who have not responded to advanced therapies.
Adult patients with refractory UC or Crohn’s disease, gastroenterologists and IBD specialists, and researchers interested in non-pharmacologic/interventional IBD treatments.
This is a retrospective multicenter cohort study of granulocyte and monocyte adsorptive apheresis (GMA) using the ADACOLUMN® system in 129 patients with refractory inflammatory bowel disease (79% ulcerative colitis, 21% Crohn’s disease) treated across 15 French tertiary centers from 2007–2024.
By week 14 about one-third of patients with either UC or CD achieved steroid-free clinical remission; response rates were higher (52% UC, 67% CD). Some patients continued maintenance GMA beyond week 14 and showed higher steroid-free remission rates at week 54 among those remaining on therapy.
The study is observational and retrospective, so it reports real-world outcomes rather than results of a randomized trial. Adverse events were noted (26 events; 16 were IBD exacerbations).
The report suggests GMA may induce remission in a subset of patients with refractory disease and that continued maintenance therapy was associated with ongoing benefit for some.
If you’re considering this treatment, discuss with your IBD team how GMA might fit alongside or after advanced therapies; this study included many patients previously exposed to biologics or small molecules. This summary is grounded in the article abstract provided by the journal; Cure8 has not reviewed the full manuscript beyond that abstract.
This is a retrospective observational cohort (real-world) study, not a randomized controlled trial; results may be affected by selection bias, lack of a control group, and variable concomitant therapies. The summary is based on the article abstract.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest Marianne Hupé declares consulting from Abbvie and Pfizer, and lecturing fees from Abbvie, Johnson&Johnson, Pfizer, Takeda, Lilly Guillaume Bouguen declares conflicts of interest with Abbvie, Amgen, Biogen, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Pfizer, Takeda, Sandoz Anthony Buisson declares consulting fees from: Abbvie, Amgen, Arena, Biogen, Celltrion Healthcare, Ferring, Galapagos, GutuCare/Resilience, Hikma, Janssen, Lilly, Mylan, Nexbiome, Pileje, Pfizer, Roche, Sandoz, Takeda and Tillotts, lecturer fees from Abbvie, Amgen, Biogen, Celltrion Healthcare, Ferring, Fresnius-Kabi, Galapagos/Alfa Sigma, Hikma, Janssen, Lilly, Mayoli-Spindler, MSD, Pfizer, Roche, Sanofi-Aventis, Takeda, Tillotts and Vifor-Pharma and research fundings from Abbvie, Celltrion Healthcare and Galapagos/Alfa, SigmaLessaffre, Lilly, Pfizer and Takeda Cecilia Landman received lecture fees or consulting fees for AbbVie, Johnson & Johnson, Tillots and Takeda Mathieu Uzan declares consulting fees and travel accommodations from Abbvie, Janssen, Takeda, Celltrion, Fresenius, Owkin, Pfizer. Stéphane Nancey declares consulting from Abbvie, Johnson&Johnson, Medac, Lilly, Takeda, Celltrion and lecturing fees from Abbvie, Johnson&Johnson, Fresenius Kabi, Medac, Pfizer, Takeda, Lilly, Celltrion Guillaume Cadiot declares consulting from Johnson&Johnson and lecturing fees from Abbvie, Takeda Cyrielle Gilletta declares advisory board and/or speaking fees from Abbvie, AlfaSigma, Amgen, Celltrion, Ferring, Fresenius Kabi, Janssen, Lilly, MSD, Pfizer, Takeda and Tillots. Lucas Guillo declares conflicts of interest with Abbvie, Amgen, Celltrion, Everzom, Ferring, Fresenius Kabi, Janssen, Johnson & Johnson, Lilly, Pfizer, Sandoz, Takeda, Tillots. Anne Wampach declares conflict of interest with Abbvie, Takeda, celltrion et Pfizer. Michael Collins declares consulting fees from Abbvie, Johnson&Johnson, Takeda, Amgen and lecturing fees from Abbvie, Johnson&Johnson, Fresenius Kabi, Pfizer, Takeda, biocon, Sandoz, sanofi Romain Altwegg declares Advisory boards from Abbvie, Takeda, Johnson and Johnson, Pfizer, Alphasigma, Amgen, Biogen, Sandoz, MSD, Ferring, Celltrion, Lilly Aurélien Amiot received consulting fees from Abbvie, Hospira, Janssen, Tillotts, Pfizer, Takeda, Gilead and Biocodex as well as lecture fees and travel accommodations from Abbvie, Janssen, Biocodex, Hospira, Ferring, Pfizer, Biogen, Amgen, Fresenius Kabi, Ferring, Tillotts, Takeda and MSD. He also received advisory board fees from Gilead, Tillotts, Takeda and Abbvie. None for the remaining coauthors.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Autoinjectors can make long-term biologic treatment easier, more convenient, and potentially improve adherence for people with Crohn’s disease or ulcerative colitis who use ustekinumab.
Elevated pancreatic enzymes are relatively common in IBD and can reflect very different conditions (benign asymptomatic elevations, pancreatitis variants, or autoimmune pancreatitis). Recognizing phenotype-specific...
The study will prospectively evaluate how often dysplasia occurs, how lesions look and behave after endoscopic resection, and what factors predict local or distant recurrence—information that could change surveillance...
